세계의 선천성 대사 오류용 의료용 식품 시장 보고서(2025년)
Medical Foods For Inborn Errors Of Metabolism Global Market Report 2025
상품코드 : 1805286
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,430,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,294,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,159,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

선천성 대사 오류용 의료용 식품 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 11.8%로 성장할 전망이며, 53억 9,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 원격 의료 통합, 클린 라벨 제품에 대한 수요 증가, 신생아 스크리닝 프로그램 확대, 환자 중심 케어 모델, 식물 유래의 지속 가능한 제제 등에 기인합니다. 예측 기간 주요 동향으로는 유전자 검사의 기술적 진보, 식품 가공 기술의 진보, 성분 기술의 혁신, 식품 배합의 기술적 진보 등이 있습니다.

향후 5년간의 성장률 11.8%라고 하는 예측은 이 시장에 관한 전회 예측으로부터 변경은 없습니다. 그러나 주로 미국과 타국가 간 관세 영향으로 스위스로부터의 특수 아미노산 블렌드 가격을 인상하고 환자 구매 능력에 영향을 미치는 것으로 미국에 직접 영향을 미칠 수 있습니다. 이러한 영향은 상호관세와 무역 긴장 증가 및 제한 증가로 인한 세계 경제와 무역에 대한 부정적인 영향으로 더욱 광범위하게 작용할 것으로 보입니다.

유전성(선천성) 질환의 유병률 증가는 앞으로 수년간 선천성 대사 오류용 의료용 식품 시장의 성장을 이끌 것으로 예측됩니다. 유전성 질환은 표준 DNA 서열의 전반적인 또는 부분적인 돌연변이에 의해 야기되는 병태입니다. 의료용 식품은 영양 부족을 예방하고 영유아의 성장과 전반적인 행복을 돕기 위해 신진 대사 장애가 있는 영유아에게 특별한 영양을 제공하는 데 중요한 역할을 하며, 영유아 특유의 신진 대사 요구를 충족하도록 조정됩니다. 예를 들어, 2024년 5월 미국의 공중위생기관인 질병대책예방센터(CDC)는 겸상적혈구증(SCD)은 미국에서 약 10만 명이 이환되고 있으며, 이환 환자의 90% 이상이 비히스패닉계 흑인 또는 아프리카계 미국인이며, 추정 3-9%가 히스패닉계 또는 라틴계라고 보고했습니다. 이와 같이 유전성 질환 증가는 선천성 대사 오류용 의료용 식품 시장의 성장에 기여하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Medical foods for inborn errors of metabolism encompass dietary supplements tailored for individuals with genetic conditions impacting metabolic functions. These products address specific nutritional needs in the management of these conditions. Key categories include amino acid formulations, glytactin with GMP amino acid-modified infant formula with iron, low-calcium/vitamin D-free infant formula with iron, low protein foods, and more. Amino acids, essential components found in living cells, are employed in medical foods for inborn errors of metabolism to offer alternative sources of crucial amino acids, bypassing those the individual's body struggles to metabolize effectively.

These medical foods cater to a range of disorders, including phenylketonuria (PKU), maple syrup urine disease (MSUD), homocystinuria, methylmalonic acidemia, organic acidurias, propionic acidemia, isovaleric acidemia, disorders of leucine metabolism, glutaric acidemia type I, renal disease, and others. Tailored for various age groups such as infants, weaning, adolescents, and adults, these products are available in diverse forms such as powders, liquids, gels, and more. Distribution channels include retail pharmacies, hospital pharmacies, drug stores, online pharmacies, and other relevant outlets.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The rapid implementation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a notable impact on the food and beverage sector. Rising costs for imported ingredients such as olive oil, cheese, and tropical fruits are pressuring food manufacturers to either reformulate their products or absorb reduced profit margins. Beverage producers are similarly affected, with tariffs on aluminum cans driving up packaging costs. Meanwhile, retaliatory tariffs on U.S. agricultural exports like soybeans and pork are disrupting farm-to-processor supply chains. In response, companies are adjusting recipes, increasing local sourcing, and using commodity hedging strategies to manage price volatility.

The medical foods for inborn errors of metabolism market research report is one of a series of new reports from The Business Research Company that provides medical foods for inborn errors of metabolism market statistics, including medical foods for inborn errors of metabolism industry global market size, regional shares, competitors with a medical foods for inborn errors of metabolism market share, detailed medical foods for inborn errors of metabolism market segments, medical foods for inborn errors of metabolism market trends and opportunities, and any further data you may need to thrive in the medical foods for inborn errors of metabolism industry. This medical foods for inborn errors of metabolism market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The medical foods for inborn errors of metabolism market size has grown rapidly in recent years. It will grow from $3.08 billion in 2024 to $3.45 billion in 2025 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to global health initiatives, increased recognition of nutritional therapies, precision medicine approaches, increasing incidence of metabolic disorders, and personalized digital nutrition platforms.

The medical foods for inborn errors of metabolism market size is expected to see rapid growth in the next few years. It will grow to " $5.39 billion in 2029 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to telehealth integration, rising demand for clean-label products, expanded newborn screening programs, patient-centric care models, and plant-based and sustainable formulations. Major trends in the forecast period include technological advancements in genetic testing, advancements in food processing technologies, innovations in ingredient technology, and technological advancements in food formulation.

The forecast of 11.8% growth over the next five years remains unchanged from the previous projection for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US by raising prices for specialized amino acid blends from Switzerland, impacting patient affordability.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of genetic (inherited) disorders is anticipated to drive the growth of the medical foods market for inborn errors of metabolism in the coming years. Genetic disorders are conditions caused entirely or partially by variations in the standard DNA sequence. Medical foods play a crucial role in providing specialized nutrition for infants with metabolic disorders, tailored to meet their unique metabolic needs, thus helping to prevent nutritional deficiencies and support their growth and overall well-being. For example, in May 2024, the Centers for Disease Control and Prevention (CDC), a U.S.-based public health agency, reported that sickle cell disease (SCD) affects approximately 100,000 individuals in the United States, with over 90% of those impacted being non-Hispanic Black or African American, and an estimated 3%-9% being Hispanic or Latino. Consequently, the rise in genetic disorders is fueling the growth of the medical foods market for inborn errors of metabolism.

The increasing aging population is projected to boost the growth of the medical food market for inborn errors of metabolism in the coming years. An aging population refers to a demographic trend marked by a growing percentage of elderly individuals within a society. Medical food for inborn errors of metabolism caters to the nutritional needs and metabolic challenges faced by older adults with specific disorders. For instance, in January 2022, the Congressional Budget Office, a U.S.-based federal agency, estimated that the population eligible for Social Security payroll taxes and benefits would rise from 342 million in 2024 to 383 million by 2054. Additionally, the global population of individuals aged 60 and older is expected to double, reaching 2.1 billion by 2050. Thus, the rising aging population is driving the growth of the medical food market for inborn errors of metabolism.

Product innovation has become a prominent trend in the medical food market for inborn errors of metabolism. Leading companies in this sector are focusing on developing cutting-edge products to enhance their market presence. For instance, in October 2023, Galen Limited, a UK-based pharmaceutical firm, introduced PKU Easy Microtabs Plus as part of its Medical Nutrition line. This product is designed to aid in the dietary management of Phenylketonuria (PKU), a metabolic disorder. PKU Easy Microtabs Plus provides patients with a more convenient and precise way to control their phenylalanine levels through small, easy-to-swallow microtabs. This innovative formulation aims to improve the quality of life for individuals with PKU by facilitating better dose customization and ease of use.

Major companies in the medical food for inborn errors of metabolism market are also directing their efforts towards developing innovative metabolic products, such as solid-dose protein substitutes, to address dietary management needs and gain a competitive edge. A notable example is Galen Medical Nutrition, an Ireland-based company, which, in October 2022, introduced TYR EASY Tablets into the UK market. These unique solid-dose protein substitutes for tyrosinemia are provided in tablet form and cater to patients over the age of 8, offering more options for protein substitutes tailored to their daily requirements.

In July 2023, Pentec Health, a US-based provider of specialty infusion services and medical foods, acquired ZOIA Pharma for an undisclosed amount. Through this acquisition, Pentec Health aims to enhance its product portfolio by incorporating the PKU GOLIKE family of medical food products, specifically designed for the dietary management of phenylketonuria (PKU). The PKU GOLIKE range offers patients innovative options to effectively manage their protein intake. ZOIA Pharma is a US-based organization dedicated to developing medical food specifically for inborn errors of metabolism.

Major companies operating in the medical foods for inborn errors of metabolism market include Nestle Health Science, Abbott Laboratories, Danone Nutricia, Vitaflo International Ltd., BioMarin Pharmaceutical Inc., Cambrooke Therapeutics Inc., Galen US Inc., Nutricia North America, Solace Nutrition LLC, Nutricia Advanced Medical Nutrition, Ajinomoto Cambrooke Inc., Primus Pharmaceuticals Inc., Applied Nutrition Corp., Metagenics Inc., PKU Perspectives Inc., Medtrition Inc., Nutricia Pty Ltd., Arla Foods Ingredients Group P/S, Aegle Nutrition LLC, Homestat Farm Ltd., Ketovie Nutrition, Formulaid, International Nutrition Inc., Phesgo Medical Foods, Immedica Pharma AB, Meiji Holdings Co. Ltd.

North America was the dominant region in the medical foods for inborn errors of metabolism market in 2024. The regions covered in the medical foods for inborn errors of metabolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the medical foods for inborn errors of metabolism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The medical food for inborn errors of the metabolism market consists of sales of galactose-free formulas, modified starches and carbohydrate supplements, and Vitamin pyridoxine (B6) supplements. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Medical Foods For Inborn Errors Of Metabolism Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on medical foods for inborn errors of metabolism market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for medical foods for inborn errors of metabolism ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The medical foods for inborn errors of metabolism market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Medical Foods For Inborn Errors Of Metabolism Market Characteristics

3. Medical Foods For Inborn Errors Of Metabolism Market Trends And Strategies

4. Medical Foods For Inborn Errors Of Metabolism Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Medical Foods For Inborn Errors Of Metabolism Growth Analysis And Strategic Analysis Framework

6. Medical Foods For Inborn Errors Of Metabolism Market Segmentation

7. Medical Foods For Inborn Errors Of Metabolism Market Regional And Country Analysis

8. Asia-Pacific Medical Foods For Inborn Errors Of Metabolism Market

9. China Medical Foods For Inborn Errors Of Metabolism Market

10. India Medical Foods For Inborn Errors Of Metabolism Market

11. Japan Medical Foods For Inborn Errors Of Metabolism Market

12. Australia Medical Foods For Inborn Errors Of Metabolism Market

13. Indonesia Medical Foods For Inborn Errors Of Metabolism Market

14. South Korea Medical Foods For Inborn Errors Of Metabolism Market

15. Western Europe Medical Foods For Inborn Errors Of Metabolism Market

16. UK Medical Foods For Inborn Errors Of Metabolism Market

17. Germany Medical Foods For Inborn Errors Of Metabolism Market

18. France Medical Foods For Inborn Errors Of Metabolism Market

19. Italy Medical Foods For Inborn Errors Of Metabolism Market

20. Spain Medical Foods For Inborn Errors Of Metabolism Market

21. Eastern Europe Medical Foods For Inborn Errors Of Metabolism Market

22. Russia Medical Foods For Inborn Errors Of Metabolism Market

23. North America Medical Foods For Inborn Errors Of Metabolism Market

24. USA Medical Foods For Inborn Errors Of Metabolism Market

25. Canada Medical Foods For Inborn Errors Of Metabolism Market

26. South America Medical Foods For Inborn Errors Of Metabolism Market

27. Brazil Medical Foods For Inborn Errors Of Metabolism Market

28. Middle East Medical Foods For Inborn Errors Of Metabolism Market

29. Africa Medical Foods For Inborn Errors Of Metabolism Market

30. Medical Foods For Inborn Errors Of Metabolism Market Competitive Landscape And Company Profiles

31. Medical Foods For Inborn Errors Of Metabolism Market Other Major And Innovative Companies

32. Global Medical Foods For Inborn Errors Of Metabolism Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Medical Foods For Inborn Errors Of Metabolism Market

34. Recent Developments In The Medical Foods For Inborn Errors Of Metabolism Market

35. Medical Foods For Inborn Errors Of Metabolism Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기